Zydus Lifesciences Limited has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach. Out of 14 lac newly diagnosed cancer patients in India, nearly 0.275 million patients are diagnosed with breast, ovarian, prostrate and pancreatic cancers as per Globocan 2022 data.

Amongst these patients, those who are diagnosed as HRD positive or with BRACA mutation need to be administered this PARP inhibitor which can delay the progression of the disease. IBYRA is a next gen targeted therapy for HRD positive and BRACA positive cancer patients. To help identify the right patients and facilitate access, Zydus has collaborated with MedGenome for comprehensive HRD testing.

This alongwith a year-long treatment of IBYRA has been capped at INR 0.3 million as compared to the cost of around INR 7.2 million by the innovator.